OMERS ADMINISTRATION Corp purchased a new position in shares of Humana Inc. (NYSE:HUM – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 6,457 shares of the insurance provider’s stock, valued at approximately $2,565,000.
Other large investors also recently modified their holdings of the company. Montag A & Associates Inc. boosted its stake in Humana by 1,880.0% during the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after acquiring an additional 94 shares in the last quarter. Johnson Financial Group Inc. bought a new stake in Humana in the second quarter valued at $26,000. Fideuram Asset Management Ireland dac acquired a new position in shares of Humana during the fourth quarter valued at about $27,000. Trust Co. of Vermont bought a new position in shares of Humana during the 2nd quarter worth about $28,000. Finally, Reflection Asset Management bought a new stake in Humana in the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 92.38% of the company’s stock.
Humana Stock Performance
Shares of Humana stock opened at $388.92 on Wednesday. Humana Inc. has a 52 week low of $163.11 and a 52 week high of $428.88. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62. The business has a 50 day moving average price of $383.88 and a 200-day moving average price of $285.00. The company has a market cap of $46.70 billion, a PE ratio of 36.79, a price-to-earnings-growth ratio of 2.20 and a beta of 0.72.
Analyst Ratings Changes
A number of research analysts recently weighed in on HUM shares. Guggenheim upped their price target on Humana from $269.00 to $471.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Cantor Fitzgerald boosted their price objective on Humana from $264.00 to $300.00 and gave the company a “neutral” rating in a report on Tuesday, July 7th. Morgan Stanley raised Humana from an “underweight” rating to an “equal weight” rating and upped their target price for the stock from $249.00 to $370.00 in a research report on Tuesday, August 4th. Royal Bank Of Canada increased their target price on Humana from $246.00 to $415.00 and gave the stock a “sector perform” rating in a report on Thursday, July 9th. Finally, Weiss Ratings upgraded shares of Humana from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, August 14th. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $403.91.
Humana Profile
Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Featured Articles
- Five stocks we like better than Humana
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
